Delft: AraGen Bioscience and Getinge announced the successful validation of its single-use production reactors (SUPRs) for mass production Recombinant antibody productionThis collaboration adds to the expertise of AraGen Bio-pharmaceutical manufacturing and Getinge’s innovative single-use technology, which enables seamless production of large-scale batches.

The validation study was conducted at AraGene’s state-of-the-art laboratory. R&D Facility in Morgan Hill, California. It demonstrated SUPR BioreactorExceptional performance in generating high-quality recombinant antibodies. The reactor is designed as a single-use alternative to conventional stainless-steel bioreactors at pilot and production scale. It allows the upstream process to continue from research to production with a reliable single-use platform. R&D and process optimization performed in AppliFlex ST or Applikon Bio can now be easily scaled up using SUPR.

“Gettinge’s 50L and 250L single-use bioreactor platforms are now available at Aragene to meet the growing demand for large-scale recombinant antibody production,” said Dr. Subodh Deshmukh, CEO of Aragene Bioscience.

Timo Walvoort, Getinge’s R&D Director, said: “Through working together, we have developed the world’s first single-use true bioreactor that is uniquely easy to use. I look forward to many more fruitful collaborations with our friends at AraGen!”

The ease of scaleup from 2 liters to 50 liters to 250 liters is one of the most challenging aspects of bioproduction. AraGen scientists used their proprietary platform process to run in the SUPR system and achieved excellent results. Critical parameters such as cell growth pattern, metabolites, osmolality, pH and production yield profile remained stable throughout the scaleup.